A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Estradiol (Primary)
  • Indications Atrophic vaginitis; Vulvovaginitis
  • Focus Therapeutic Use
  • Sponsors TherapeuticsMD
  • Most Recent Events

    • 22 Sep 2016 According to a TherapeuticsMD media release, data of this trial will be presented at annual meetings of the International Menopause Society (IMS) and the North American Menopause Society (NAMS), 2016.
    • 22 Oct 2013 Status changed from recruiting to completed.
    • 12 Aug 2013 Status changed from planning to recruiting, according to a TherapeuticsMD media release; 44% of patients have been enrolled to date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top